Race Oncology CEO Damian Clark-Bruce joined Steve Darling from Proactive to share significant news about the company's recent agreements and partnerships.
Firstly, Race Oncology has signed an agreement with Ardena Holding, a global contract development and manufacturing organization. This collaboration will provide additional Good Manufacturing Practice -standard manufacturing capability for its flagship IV formulation of bisantrene, RC220. Ardena is a fully integrated CDMO known for its expertise in assisting biopharma companies throughout the drug development life cycle, including the production of sterile injectable products for clinical development.
Clark-Bruce further explained to Proactive that this partnership with Ardena strengthens Race Oncology's existing manufacturing programs, as it establishes a primary source for EU-compliant supplies of RC220. This is particularly important for EU clinical studies, ensuring the availability of high-quality, GMP-compliant formulations of RC220.
Additionally, Clark-Bruce shared news about an exclusive license agreement with City of Hope, a prominent US cancer research and treatment organization. Through this agreement, Race Oncology gains access to City of Hope's intellectual property, which highlights bisantrene as a potent inhibitor of the human fat mass and obesity-associated protein. This discovery opens up new possibilities for exploring the therapeutic potential of bisantrene beyond its established use as an anti-cancer agent.
View source version on newsdirect.com: https://newsdirect.com/news/race-oncology-announces-deal-with-manufacturer-ardena-to-develop-companys-new-iv-formulation-rc220-160803941
Race Oncology Ltd
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No DigiShor journalist was involved in the writing and production of this article.
© 2017 VictorThemes - Elite Themeforest Author.